Market Research Logo

China Cancer Drug Market: Size, Trends & Forecasts (2018-2022)

China Cancer Drug Market: Size, Trends & Forecasts (2018-2022)

Scope of the Report

The report entitled “China Cancer Drug Market: Size, Trends & Forecasts (2018-2022)”, provides analysis of the China cancer drug market, with detailed analysis of market size and growth, and value of the industry. The analysis includes the market by value, by cases and incidence ratio.

Moreover, the report also assesses the key opportunities in the market and outlines the factors that are and will be driving the growth of the industry. Growth of the overall China cancer drug market has also been forecasted for the years 2018-2022, taking into consideration the previous growth patterns, the growth drivers and the current and future trends.

Celgene, Novartis, Roche and Johnson & Johnson are some of the key players operating in the China cancer drug market, whose company profiling has been done in the report. In this segment of the report, business overview, financial overview and business strategies of the companies are provided.

Company Coverage

Celgene
Novartis
Roche
Johnson & Johnson

  Executive Summary

Cancer is a complex disease where uncontrolled growth of abnormal cells arises. Cancer is the process where new cell formation slows or start dividing, and form lumps. Cancer cells are different from normal cells. Cancer cells ignores signal of the body, evade the immune system and do not specialize in functioning.

There are various types of cancer in the world such as prostate cancer, lung & bronchus cancer, colon & rectum cancer, bladder cancer, breast cancer, kidney and renal pelvis cancer, thyroid cancer, endometrial cancer and others. For different cancer, different types of treatments are available in the market such as chemotherapy, surgery, radiation therapy, targeted therapies, immunotherapy, hormonal therapy, angiogenesis inhibitors and synthetic lethality.

There are different categories of anti-cancer drugs such as classic cytotoxic agents (alkylating agents, antimetabolites, and anti-microtubule agents, etc.), target-based anticancer drugs (selective or semi-selective), biologics or immunotherapy and hormones and hormone antagonists.

Chemotherapy is the most common cancer treatment. But there are few side-effects which are associated with chemotherapy treatment displaying different side effcets on different patients such as fatigue, hair loss, diarrhea, weight change, easy bruising and bleeding, nausea and vomiting, etc.

The China Cancer Drug Market is expected to increase at high growth rates during the forecasted period (2018-2022). The china cancer drug market is supported by various growth drivers, such as rising aging population, stress resulting in increasing cancer cases, introduction of cutting edge therapy, rising incidence ratio, etc. The market faces certain challenges, such as, cross-border consultation, failure of clinical trial, etc. few new market trends are also provided such as, accelerated approval for advanced cancer drugs, combination therapy, etc.


1. Executive Summary
2. Introduction
2.1 Cancer: An Overview
2.1.1 Cancer: Meaning
2.1.2 Difference Between Normal and Cancer Cells
Table 1: Difference Between Normal and Cancer Cells
2.1.3 Types of Cancer
Table 2: Types of Cancer
2.1.4 Treatments of Cancer
Table 3: Different Treatments of Cancer
2.1.5 Classification of Anticancer Drugs
Table 4: Classification of Anticancer Drugs
2.1.6 Side Effects of Chemotherapy
Table 5: Side Effects of Chemotherapy
3. Global Market Analysis
3.1 Global Cancer Drug Market: An Analysis
3.1.1 Global Cancer Drug Market by Value
Table 6: Global Cancer Drug Market by Value; 2015-2017 (US$ Billion)
Table 7: Global Cancer Drug Market by Value; 2018-2022 (US$ Billion)
3.1.2 Global Cancer Drug Market by Region (China and Rest of the World)
Table 8: Global Cancer Drug Market by Region (China and Rest of the World); 2017 (Percentage, %)
3.2 Global Cancer Drug Market: Product Analysis
3.2.1 Global PD-1 Market by Value
Table 9: Global PD-1 Market by Value; 2016-2017 (US$ Billion)
Table 10: Global PD-1 Market by Value; 2018-2022 (US$ Billion)
3.2.2 Global PD-1 Market by Type of Product
Table 11: Global PD-1 Market by Type of Product; 2016-2017 (US$ Billion)
3.2.3 Global Zanubrutinib (Excluding China) Market by Value
Table 12: Global Zanubrutinib (Excluding China) Market by Value; 2020-2022 (US$ Million)
4. China Market Analysis
4.1 China Cancer Drug Market: An Analysis
4.1.1 China Cancer Drug Market by Value
Table 13: China Cancer Drug Market by Value; 2011-2017 (US$ Billion)
Table 14: China Cancer Drug Market by Value; 2018-2022 (US$ Billion)
4.1.2 China Cancer Cases
Table 15: China Cancer Cases; 2013-2017 (Million)
4.1.3 Incidence of Types of Cancer of Cancer of China Out of the World
Table 16: Incidence of Types of Cancer of China Out of the World ; 2015
4.2 China Cancer Drug Market: Product Analysis
4.2.1 China PD-1 Market by Value
Table 17: China PD-1 Market by Value; 2020-2022 (US$ Billion)
4.2.2 China Zanubrutinib Market by Value
Table 18: China Zanubrutinib Market by Value; 2019-2022 (US$ Million)
5. Market Dynamics
5.1 Growth Drivrs
5.1.1 Rising Aging Population
Table 19: China Population Above 65 years; 2011-2016 (Billion)
Table 20: China Colorectal Cancer Trend; 2000-2030
5.1.2 Rising Incidence Ratio
Table 21: Mortality-Incidence Ratio; 2016
5.1.3 Stress Resulting in Increasing Cancer Cases
Table 22: Stress and Worry Penetration in Chinese Population; 2011-2016 (Percentage, %)
5.1.4 Growing Urban Population
Table 23: China Urban Population; 2011-2016 (Million)
5.1.5 Increasing GNI Per Capita in China
Table 24: China GNI Per Capita; 2011-2016 (US$)
Table 25: Patients Access to New Oncology Drugs; 2011-2016 (Thousand)
5.1.6 Introduction of Cutting Edge Therapy
Table 26: Types of Cutting Edge Treatments
5.1.7 Changing Lifestyle and Rising Awareness
5.1.8 Public Medical Insurance
5.2 Challenges
5.2.1 Cross-Border Consultation
Table 27: Chinese Patients Cross-Border Consultation; 2016 (Percentage,%)
5.2.2 Failure of Clinical Trial
5.3 Market Trends
5.3.1 Accelerated Approval for Advanced Cancer Drugs
Table 28: Cancer Drugs Approved from the Priority Review List; 2017
5.3.2 Combination Therapy
Table 29: Expected Sales of Combined Therapies in China; 2021-2025
5.3.3 Exemption of Import Tariff on Cancer Drugs
6. Competitive Landscape
6.1 China Cancer Drug Market: Top Players Analysis
Table 30: China Cancer Drug Market Player Comparison
7. Company Profiling
7.1 Celgene
7.1.1 Business Overview
7.1.2 Financial Overview
Table 31: Celgene Revenue; 2013-2017 (US$ Billion)
Table 32: Celgene Revenue by Product; 2017 (Percentage, %)
Table 33: Celgene Revenue by Region; 2017 (Percentage, %)
7.1.3 Business Strategy
7.2 Novartis
7.2.1 Business Overview
7.2.2 Financial Overview
Table 34: Novartis Net Sales; 2013-2017 (US$ Billion)
Table 35: Novartis Net Sales by Segment; 2017 (Percentage, %)
Table 36: Novartis Net Sales by Region; 2017 (Percentage, %)
7.2.3 Business Strategy
7.3 Roche
7.3.1 Business Overview
7.3.2 Financial Overview
Table 37: Roche Sales; 2013-2017 (US$ Billion)
Table 38: Roche Sales by Segment; 2017 (Percentage, %)
Table 39: Roche Sales by Region; 2017 (Percentage, %)
7.3.3 Business Strategy
7.4 Johnson & Johnson
7.4.1 Business Overview
7.4.2 Financial Overview
Table 40: Johnson & Johnson Sales; 2013-2017 (US$ Billion)
Table 41: Johnson & Johnson Sales by Segment; 2017 (Percentage, %)
Table 42: Johnson & Johnson Sales by Region; 2017 (Percentage, %)
7.4.3 Business Strategy

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report